SynWaiXen · Total Synthesis of Waixenicin A and Xenibellol A
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2020-03-01 → 2022-02-28
- EU contribution
- €174,167
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Total Synthesis of Waixenicin A and Xenibellol A
The realization of the first total syntheses of the two marine natural products waixenicin A and xenibellol A is the aim of this proposal. For this purpose, a N-heterocyclic carben (NHC)-catalyzed bicyclization shall be employed as key transformation. Both target structures are members of the Xenia diterpenoids family and exhibit cytotoxicity against human cancer cell lines. Despite these highly desirable, promising biological properties and unique structural features, therapeutic applications have been prevented by the circumstance that no synthetic access has been achieved until this day. Using retrosynthetic pattern recognition, we realized that the central fused lactone motif (of both natural products) could be efficiently accessed via a recently reported NHC-catalyzed bicyclization reaction. This organocatalytic methodology enables a rapid creation of molecular complexity and, therefore, its application to these total syntheses should save time and other resources. If a therapeutic potential can be corroborated, a synthetic access would provide this family of Xenia diterpenoids (or their derivatives) as possible anticancer drugs. As a result, this project could potentially lead to an improvement of medical care for future cancer patients, thereby also addressing a UN sustainable development goal.
Data: CORDIS, © European Union
Project objective
The realization of the first total syntheses of the two marine natural products waixenicin A and xenibellol A is the aim of this proposal. For this purpose, a N-heterocyclic carben (NHC)-catalyzed bicyclization shall be employed as key transformation. Both target structures are members of the Xenia diterpenoids family and exhibit cytotoxicity against human cancer cell lines. Despite these highly desirable, promising biological properties and unique structural features, therapeutic applications have been prevented by the circumstance that no synthetic access has been achieved until this day. Using retrosynthetic pattern recognition, we realized that the central fused lactone motif (of both natural products) could be efficiently accessed via a recently reported NHC-catalyzed bicyclization reaction. This organocatalytic methodology enables a rapid creation of molecular complexity and, therefore, its application to these total syntheses should save time and other resources. If a therapeutic potential can be corroborated, a synthetic access would provide this family of Xenia diterpenoids (or their derivatives) as possible anticancer drugs. As a result, this project could potentially lead to an improvement of medical care for future cancer patients, thereby also addressing a UN sustainable development goal.
Original text from CORDIS.
Participants
- UNIVERSITAET INNSBRUCK · InnsbruckCoordinatorAustria
Links
Data: CORDIS, © European Union